US 11667643
RIP1K inhibitors
granted A61PA61P25/00A61P29/00
Quick answer
US patent 11667643 (RIP1K inhibitors) held by Rigel Pharmaceuticals, Inc. expires Mon Jun 01 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Rigel Pharmaceuticals, Inc.
- Grant date
- Tue Jun 06 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jun 01 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 19
- CPC classes
- A61P, A61P25/00, A61P29/00, A61P37/00, A61P9/00